Prefilled Syringes Market to Record CAGR of 11.4% Over 2024-2032; Increasing Need for Biologics to Drive Market Growth

The global prefilled syringes market size was valued at USD 7.91 billion in 2023 and is predicted to reach USD 8.70 billion in 2024. The market is anticipated to touch USD 20.62 billion by 2032, recording a CAGR of 11.4% over 2024-2032.

Fortune Business Insights™ presents this information in its latest report titled “Prefilled Syringes Market Size, Share & Industry Analysis, By Material (Glass and Plastic), By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System), By Product (Complete Syringe Set and Components & Accessories), By Application (Cancer, Rheumatoid Arthritis, Diabetes, and Others), By Design (Single-chamber, Double-chamber, and Multiple-chamber), By End User (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others), and Regional Forecast, 2024-2032”.

Prefilled syringes are specialized containers for injectable drug delivery designed for administration via the parenteral route. They offer numerous advantages, including reduced contamination risks, minimized drug wastage from overfilling, elimination of dosing errors, expedited drug delivery during emergencies, and user-friendly operation. These benefits are anticipated to drive the demand for prefilled syringes.

The COVID-19 pandemic significantly influenced the market primarily due to the heightened demand for pre-filled products. The surge in the demand for vaccine necessitated an increase in manufacturing capacity for these syringes, resulting in enhanced revenue for manufacturers and positively affecting market dynamics.

Increasing Need for Biologics to Drive Market Growth

The increasing need for biologics is driving the development of cutting-edge injectable drug delivery systems. This advancement is fueling a substantial demand for prefilled syringes. The heightened demand for manufacturers to obtain regulatory approvals is expected to contribute to the global expansion of the prefilled syringes market in the coming years. Moreover, the escalating incidence of cancer, autoimmune disorders, and other non-communicable diseases is anticipated to augment the demand for biological drugs.

However, the prefilled syringes market growth is constrained by factors such as stringent regulatory requirements and manufacturing intricacies.

Fresenius Kabi AG Obtained Approval from U.S. FDA for its Biosimilar Idacio Intended for Treatment of Chronic Autoimmune Diseases

Fresenius Kabi AG obtained approval from the U.S. FDA for its biosimilar Idacio (adalimumab), intended for the treatment of chronic autoimmune diseases. The medication will be offered in a self-administered pre-filled syringe and a self-administered pre-filled pen.

Companies to Invest in Innovative Product Development to Strengthen their Market Dominance

Becton Dickinson and Company (B.D.), Gerresheimer AG, SCHOTT AG, and West Pharmaceutical Services Inc. comprised the majority of the global prefilled syringes market share in 2023. These companies are poised to sustain their dominance and generate significant revenue in the years ahead. Their leadership is largely due to research efforts and continuous investments in innovative product development aimed at creating a cost-effective and highly efficient parenteral drug delivery system.

Notable Industry Development:

• September 2022: BD, a leading medical technology company, introduced its next-generation prefillable vaccine syringe to enhance the efficiency and reliability of vaccine delivery. The launch of this syringe has helped the company enhance its brand visibility.

List of the Companies Profiled in the Report:

• BD (U.S.)


• Gerresheimer AG (Germany)


• SCHOTT AG (Germany)


• West Pharmaceutical Services Inc. (U.S.)


• Helvoet Rubber & Plastic Technologies BV (Netherlands)


• NIPRO (Japan)


• AptarGroup, Inc. (U.S.)


• Terumo Corporation (Japan)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/prefilled-syringes-market-101946

Further Report Findings

• The European region led the global market in 2023, achieving a revenue of USD 3.19 billion.  The rising number of patients opting for biologics to treat chronic diseases, coupled with the widespread adoption of advanced delivery methods, are significant factors expected to drive demand in the region.


• North America is projected to secure the second-largest market share primarily due to an increase in chronic diseases, such as diabetes and rheumatoid arthritis. These conditions are anticipated to elevate the need for extended drug administration at appropriate dosages.


• Based on application, the rheumatoid arthritis segment led the global market in 2023, driven by a growing prevalence of the disease, which has led to more patient admissions in healthcare settings.

Table of Segmentation